FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject
o Section 16. Form 4 or Form 5
obligations may continue. See
nstruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Cano Health, Inc.						2. Issuer Name and Ticker or Trading Symbol MSP Recovery, Inc. [LIFW]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner					
(Last)	(Fir	,	Middle))	02/2	3. Date of Earliest Transaction (Month/Day/Year) 02/27/2024								Officer (give title below)			belo	·	
9725 NW 117TH AVENUE					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(Street) MIAMI	FL	3	33178										Form filed by More than One Reporting Person						
(City)	(Sta	ate) (2	Zip)		Rul	Rule 10b5-1(c) Transaction Indication													
		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																	
		Table	I - N	on-Deriva	tive \$	Secu	rities	Ac	quirec	d, Di	sposed of	, or B	enefici	ally Owi	ned				
Date			Date	Transaction ate Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)				Disposed Of	s Acquired (A) or Of (D) (Instr. 3, 4 and		Securit Benefic Owned	5. Amount of Securities Beneficially Owned Following Reported		nership : Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price	Transa (Instr. 3	ction(s)			(Instr. 4)	
Class A Common Stock 02/27/				02/27/20)24				S		12,000	D	\$0.81	4,728,206		I		See Footnote ⁽²⁾	
Class A Common Stock 02/28/20				24				S		36,841	D	\$0.820	4,69	4,691,365		I	See Footnote ⁽²⁾		
Class A Common Stock 02/29				02/29/20	024				S		45,547	D	\$0.84	4,64	4,645,818		I	See Footnote ⁽²⁾	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execu	eemed ution Date, th/Day/Year)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration D		Date	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownersi Form: Direct (E or Indire (I) (Instr.	Beneficial Ownership (Instr. 4)		
				Code		v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amount or Number of Shares						

- 1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$0.8043 to \$0.82. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range
- 2. Reflects securities held directly by Cano Health, LLC, an indirect subsidiary of the Issuer.
- 3. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$0.81 to \$0.825. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$0.81 to \$0.862. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

Cano Health, Inc., By: /s/ David J. Armstrong, Name: David J. Armstrong, Title:

02/29/2024

General Counsel

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.